SCHEMBL22734402

SCHEMBL22734402

CCCCCCOc1ccc(CC(COCC)n2cnc3cnc4ccccc4c32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 1/20 0.41
ITGA4 P13612 1/20 0.41
TLR7 Q9NYK1 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RAB9A P51151 4/20 0.36
HPGD P15428 3/20 0.36
NPC1 O15118 3/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
GAA P10253 2/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22734411 1.00 ITGB1 (0.41) ITGB1ITGA4TLR7SMN1; SMN2LMNA
SCHEMBL30810218 1.00 ITGB1 (0.41) ITGB1ITGA4TLR7SMN1; SMN2LMNA
SCHEMBL30810166 1.00 ITGB1 (0.41) ITGB1ITGA4TLR7SMN1; SMN2LMNA
SCHEMBL22734446 1.00 ITGB1 (0.41) ITGB1ITGA4TLR7SMN1; SMN2LMNA
SCHEMBL22734444 1.00 ITGB1 (0.41) ITGB1ITGA4TLR7SMN1; SMN2LMNA
SCHEMBL30810203 1.00 ITGB1 (0.41) ITGB1ITGA4TLR7SMN1; SMN2LMNA
SCHEMBL22734400 1.00 ITGB1 (0.41) ITGB1ITGA4TLR7SMN1; SMN2LMNA
SCHEMBL22734412 1.00 ITGB1 (0.41) ITGB1ITGA4TLR7SMN1; SMN2LMNA
SCHEMBL22734470 0.97 ITGB1 (0.39) ITGB1ITGA4TLR7SMN1; SMN2LMNA
SCHEMBL22734471 0.97 ITGB1 (0.39) ITGB1ITGA4TLR7SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3759107-B1 SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-12-04 EP disclosed
US-11370788-B2 Substituted imidazo[4,5-c]quinoline compounds with an N-1 branched group 3M INNOVATIVE PROPERTIES COMPANY (US) 2022-06-28 US disclosed
US-20200385379-A1 SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2020-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11370788-B2 Substituted imidazo[4,5-c]quinoline compounds with an N-1 branched group IFNG, IFNAR1, IRF3 ITGB1 1554/4885ITGA4 2176/4885TLR7 35/4885
US-20200385379-A1 SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP IFNG, IFNAR1, IRF3 ITGB1 2908/4885ITGA4 2568/4885TLR7 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.